JP5087280B2 - 中枢神経系障害の治療のための、選択されたn−3系脂肪酸の高度濃縮組成物の使用 - Google Patents
中枢神経系障害の治療のための、選択されたn−3系脂肪酸の高度濃縮組成物の使用 Download PDFInfo
- Publication number
- JP5087280B2 JP5087280B2 JP2006550032A JP2006550032A JP5087280B2 JP 5087280 B2 JP5087280 B2 JP 5087280B2 JP 2006550032 A JP2006550032 A JP 2006550032A JP 2006550032 A JP2006550032 A JP 2006550032A JP 5087280 B2 JP5087280 B2 JP 5087280B2
- Authority
- JP
- Japan
- Prior art keywords
- ethyl ester
- schizophrenia
- composition according
- drug
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
a)アルファ−リノレン酸(ALA, C18:3 n−3)及び/又は医薬的に許容できるその誘導体及び/又は前駆体、又は
b)ドコサヘキサエン酸(DHA, C22:6 n−3)及び/又は医薬的に許容できるその誘導体及び/又は前駆体、又は
c)エイコサペンサエン酸(EPA, C20:5 n−3)とそれぞれ1:0.5ないし1:1.7、好ましくは1:0.9ないし1:1.5の比で混合したDHA及び/又は医薬的に許容できるその誘導体及び/又は前駆体、
のいずれかを含み、a)又はb)又はc)が前記組成物中の総脂肪酸重量の70重量%以上の濃度である組成物の、精神医学的関連性及び神経学的タイプの両者に関する中枢神経系(CNS)の障害の予防及び/又は治療のための薬物の調製のための使用に言及する。
統合失調症の治療において、フェノチアジン、チオキサンテン、ジベンゾアゼピン、ブチロフェノン、インドロン、フェニルピペリジン及びジフェニルピペリジン、等の群の薬物、中でもクロルプロマジン、チオリダジン、ハロペリドール、スルピリド、及びピモジド等、その他の代表的な神経遮断薬、及びクロザピン、クエチアピン、オランザピン、セルチンドール、リスペリドン、ジプラシドン、アミスルピリド(amisulpiride)及びその他のような抗精神病の「不定型の」薬剤、
大鬱病及び躁鬱病の治療において、アミトリプチリン及びその他のような三環式ノルエピネフリン再取り込み阻害剤の群、フルオキセチン、パロキセチン、セルトラリン及びその他のようなセロトニン再取り込み阻害剤の群、フェネルジン及びその他のようなモノアミンオキシダーゼ(MAO)阻害剤の群、ブプロピオン及びトラゾドンのような「不定型の」薬物の群に関する抗鬱剤、リチウム塩のような抗躁剤、ベンゾジアゼピン及び上述の抗鬱剤及び抗躁剤並びにカルバマゼピン及びバルプロ酸のようないくつかの抗痙攣剤または抗癲癇剤を含む多くの抗不安剤として気分障害及び情動障害に作用する前記薬物。
上述のCNS障害の予防及び/又は治療における本発明の使用に適した組成物の効力、並びにそれらの医薬的及び臨床的使用の可能性は、ヒトにおける検査に適切な倫理上の密接な関係のない、小動物(マウス、ラット)に関する幅広い検査を可能にするいくつもの薬理学的検査後に示されてきた。
結果:発作のある反応する動物
3/15(グループ1、処置群)
14/15(グループ2、コントロール群)
16.36±3.20(グループ1、処置群)
3.26±1.54(グループ2、コントロール群)
45±12(グループ1、処置群)
338±55(グループ2、ポジティブコントロール)
Claims (12)
- ドコサヘキサエン酸(DHA、C22:6、n−3)とエイコサペンタエン酸(EPA、C20:5、n−3)とを1:0.5〜1:1.7の重量比で含有する組成物であって、脂肪酸の全重量に対して、
(a)DHAエチルエステル34重量%より大及びEPAエチルエステル40重量%より大であって、EPAエチルエステル+DHAエチルエステル85重量%より大である、又は
(b)DHAエチルエステル34重量%より大及びEPAエチルエステル40重量%より大であって、EPAエチルエステル+DHAエチルエステル80重量%より大であり、前記n−3系酸の総エチルエステル90重量%より大である、
のいずれかを含む、統合失調症及び躁鬱症候群から選択される中枢神経系(CNS)の精神病性障害の予防及び/又は治療用組成物。 - DHAエチルエステルとEPAエチルエステルとを含み、
DHAエチルエステル80重量%より大及びEPAエチルエステル15重量%未満であって、EPAエチルエステル+DHAエチルエステル85重量%より大である、統合失調症、躁鬱症候群及び大鬱病から選択される中枢神経系(CNS)の精神病性障害の予防及び/又は治療用組成物。 - 統合失調症が陰性及び/又は陽性の症候を示す請求項1又は2に記載の組成物。
- 統合失調症が妄想性統合失調症、緊張病性統合失調症、混乱性(disorganised)統合失調症又は未分化の統合失調症である請求項1又は2に記載の組成物。
- 躁鬱症候群及び大鬱病が、活動、睡眠及び欲求と相関する気分、行動及び自律機能の障害を含む請求項1又は2に記載の組成物。
- 薬物が経口経路により投与される請求項1〜5のいずれか1つに記載の組成物。
- 薬物が軟質ゼラチンカプセルの形態にある請求項1〜6のいずれか1つに記載の組成物。
- 薬物が0.1〜5g/日の用量で投与される請求項1〜7のいずれか1つに記載の組成物。
- 薬物が0.3〜3g/日の用量で投与される請求項1〜8のいずれか1つに記載の組成物。
- 薬物が1〜2g/日の用量で投与される請求項1〜9のいずれか1つに記載の組成物。
- 薬物が、協力剤又は補助剤として、CNSの障害の予防及び/又は治療に効果的な少なくとも一つの別の薬物と別個に投与される請求項1〜10のいずれか1つに記載の組成物。
- 薬物がCNSの障害の予防及び/又は治療のために効果的な少なくとも一つの別の薬物を含む請求項1〜11のいずれか1つに記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A000069 | 2004-01-21 | ||
IT000069A ITMI20040069A1 (it) | 2004-01-21 | 2004-01-21 | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
PCT/EP2005/000522 WO2005070411A1 (en) | 2004-01-21 | 2005-01-20 | USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007518764A JP2007518764A (ja) | 2007-07-12 |
JP2007518764A5 JP2007518764A5 (ja) | 2008-03-06 |
JP5087280B2 true JP5087280B2 (ja) | 2012-12-05 |
Family
ID=34803698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006550032A Expired - Fee Related JP5087280B2 (ja) | 2004-01-21 | 2005-01-20 | 中枢神経系障害の治療のための、選択されたn−3系脂肪酸の高度濃縮組成物の使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8829048B2 (ja) |
EP (1) | EP1706106B9 (ja) |
JP (1) | JP5087280B2 (ja) |
DE (1) | DE602005015415D1 (ja) |
DK (1) | DK1706106T3 (ja) |
ES (1) | ES2329809T3 (ja) |
HR (1) | HRP20090550T1 (ja) |
IT (1) | ITMI20040069A1 (ja) |
PL (1) | PL1706106T3 (ja) |
PT (1) | PT1706106E (ja) |
RS (1) | RS51195B (ja) |
WO (1) | WO2005070411A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
EP1772146A1 (en) * | 2005-10-03 | 2007-04-11 | Neuropharma, S.A. | Polyunsaturated fatty acids as bace inhibitors |
CA2634139C (en) | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
WO2007071733A2 (en) | 2005-12-21 | 2007-06-28 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
EP2144618B1 (en) | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US20110166229A1 (en) | 2008-09-09 | 2011-07-07 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
AU2016217566B2 (en) | 2015-02-11 | 2019-02-14 | Aker Biomarine Human Ingredients As | Lipid compositions |
KR20170118125A (ko) | 2015-02-11 | 2017-10-24 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 추출 공정 |
EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
PL238670B1 (pl) * | 2018-07-06 | 2021-09-20 | Skotan Spolka Akcyjna | Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych |
JPWO2022050355A1 (ja) * | 2020-09-04 | 2022-03-10 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
IT1205043B (it) * | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
DE3739700A1 (de) | 1987-11-24 | 1989-06-08 | Guenther Dr Med Jeschke | Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin |
JP2524217B2 (ja) | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
GB2218904A (en) | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
FR2688145B1 (fr) | 1992-03-06 | 1994-09-23 | Borden France Sa | Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur. |
JPH0672868A (ja) * | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
DK1157692T3 (da) | 2000-05-22 | 2006-02-06 | Pro Aparts Investimentos E Con | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf |
IT1320180B1 (it) | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
-
2004
- 2004-01-21 IT IT000069A patent/ITMI20040069A1/it unknown
-
2005
- 2005-01-20 DK DK05701068T patent/DK1706106T3/da active
- 2005-01-20 PT PT05701068T patent/PT1706106E/pt unknown
- 2005-01-20 RS RSP-2009/0437A patent/RS51195B/sr unknown
- 2005-01-20 US US10/586,863 patent/US8829048B2/en not_active Expired - Fee Related
- 2005-01-20 ES ES05701068T patent/ES2329809T3/es active Active
- 2005-01-20 PL PL05701068T patent/PL1706106T3/pl unknown
- 2005-01-20 EP EP05701068A patent/EP1706106B9/en not_active Revoked
- 2005-01-20 WO PCT/EP2005/000522 patent/WO2005070411A1/en active Application Filing
- 2005-01-20 DE DE602005015415T patent/DE602005015415D1/de active Active
- 2005-01-20 JP JP2006550032A patent/JP5087280B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-15 HR HR20090550T patent/HRP20090550T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT1706106E (pt) | 2009-09-04 |
US8829048B2 (en) | 2014-09-09 |
US20070161705A1 (en) | 2007-07-12 |
ITMI20040069A1 (it) | 2004-04-21 |
DK1706106T3 (da) | 2009-10-12 |
EP1706106A1 (en) | 2006-10-04 |
JP2007518764A (ja) | 2007-07-12 |
DE602005015415D1 (de) | 2009-08-27 |
PL1706106T3 (pl) | 2009-12-31 |
HRP20090550T1 (hr) | 2010-01-31 |
EP1706106B9 (en) | 2009-09-16 |
RS51195B (sr) | 2010-10-31 |
EP1706106B1 (en) | 2009-07-15 |
ES2329809T3 (es) | 2009-12-01 |
WO2005070411A1 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5087280B2 (ja) | 中枢神経系障害の治療のための、選択されたn−3系脂肪酸の高度濃縮組成物の使用 | |
US11253497B2 (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
CN100423718C (zh) | 治疗精神性和神经性疾病的高纯乙基epa及其他epa衍生物 | |
SK286523B6 (sk) | Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu | |
JPH0232017A (ja) | 精神分裂症および/または関連した晩発性運動障害の治療のための薬剤を製造する方法 | |
CA2344407C (en) | Method for the treatment of mania and bipolar disorder | |
DK2691086T3 (en) | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | |
CN1233955A (zh) | 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂 | |
JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
JP2014515928A (ja) | 認知機能減退に対する医療食品 | |
US20140343143A1 (en) | Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances | |
AU2004235641B2 (en) | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders | |
JPH09132553A (ja) | ドーパミンまたはL−ドーパのn−3系不飽和脂肪酸誘導体 | |
AU2006201772A1 (en) | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders | |
JPH05117147A (ja) | 痴呆疾患の治療または予防の為の組成物と、それを処方物にした抗痴呆薬 | |
MXPA97007269A (en) | A method of treatment of mania and disorderbipo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110706 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110825 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110825 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110825 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110920 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110907 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120319 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120327 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120406 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120814 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120910 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5087280 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |